The Effect Of AVANDIA On The Late Asthmatic Response

Phase 1CompletedNCT00318630

GlaxoSmithKline26 enrolled

Overview

This study is to investigate the effects of AVANDIA on the asthmatic response.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Enrollment

Conditions

Asthma

Interventions

RosiglitazoneDRUG

Rosiglitazone will be given as immediate release tablet of 4 milligrams administered orally for 28 days.

PlaceboDRUG

Subjects will also receive placebo oral tablet.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion criteria: * Mild asthmatic treated with short-acting beta agonists only, non-smoker. Exclusion criteria: * Inability to abstain from medications other than short-acting beta agonists and paracetamol. * Recent administration of steroids. * Recent respiratory infection or exacerbation of asthma.

Locations (1)

GSK Investigational Site

Wellington, New Zealand

Outcomes

Primary Outcomes

The effect of repeat oral doses of AVANDIA for 28 days on the late asthmatic response to inhaled allergen. Measured as lung function 4-10 hours after allergen challenge after 28 days dosing.

Time frame: Up to 43 days

Secondary Outcomes

The early asthmatic response to allergen, bronchial challenge, nitric oxide, markers of inflammation and safety/tolerability.

Time frame: Up to 43 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.